Values as of: 2024-09-18
COMMON STOCK | Medical Devices |
Last Closing
USD 30.52Change
0.00 (0.00)%Market Cap
USD 28.54BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease. In addition, the company offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. Further, it provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental solutions; and grooming and beauty products and solutions. The company has strategic partnership agreements with TriHealth, Northwell, and Atrium Health. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Company Website : https://www.philips.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| SEMHF | Siemens Healthineers AG |
N/A |
USD 64.87B |
| SMMNY | Siemens Healthineers AG ADR |
-0.11 (-0.40%) |
USD 61.58B |
| SONVF | Sonova Holding AG |
-14.39 (-4.06%) |
USD 20.85B |
| SNNUF | Smith & Nephew plc |
N/A |
USD 13.71B |
| WILLF | Demant A/S |
N/A |
USD 9.10B |
| GNGBF | Getinge AB |
N/A |
USD 5.88B |
| AMBFF | Ambu A/S |
+1.00 (+5.13%) |
USD 5.27B |
| AMBBY | Ambu A/S |
N/A |
USD 5.27B |
| GGNDF | GN Store Nord A/S |
N/A |
USD 3.66B |
| GNNDY | GN Store Nord A/S ADR |
-1.30 (-1.71%) |
USD 3.42B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 31.27% | 79% | B- | 80% | B- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 31.27% | 79% | B- | 79% | B- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 42.92% | 81% | B- | 83% | B | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 42.92% | 81% | B- | 82% | B | ||
| Trailing 5 Years | |||||||
| Capital Gain | -36.61% | 63% | D | 44% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -36.61% | 61% | D- | 43% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -6.88% | 36% | F | 26% | F | ||
| Dividend Return | -6.86% | 35% | F | 24% | F | ||
| Total Return | 0.01% | 4% | F | 3% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 37.68% | 78% | C+ | 62% | D | ||
| Risk Adjusted Return | -18.21% | 30% | F | 25% | F | ||
| Market Capitalization | 28.54B | 98% | N/A | 96% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
